Vyome completes pharma pivot, exits weight-loss devices; remediated all control weaknesses

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 20, 2025 · ~2 min read

Key Changes

• high

  Company completed merger with Vyome Therapeutics in August 2025 and sold all ReShape weight-loss device assets to Biorad for $2.25M, transforming into a clinical-stage pharma company developing immune-inflammatory therapies. Revenue collapsed from $1.1M to $32K quarter-over-quarter.

  MD&A: Business Transformation verify on EDGAR →
• high

  Remediated all six material weaknesses disclosed in prior period, including control environment deficiencies, journal entry segregation conflicts, IT security gaps, and income tax accounting errors that previously required financial statement restatements.

  Controls and Procedures verify on EDGAR →
• high

  Lead drug candidate VT-1953 (topical gel for malignant fungating wounds) planning FDA pivotal trial discussions in H1 2026. Current cash of $8.8M funds operations for 15 months including trial initiation, but insufficient to complete trial without additional capital.

  MD&A: Pipeline and Liquidity verify on EDGAR →